RBC Capital analyst Douglas Miehm assigned a Buy rating to Aurinia Pharmaceuticals (AUPH – Research Report) yesterday and set a price target of $8.00. The company’s shares closed yesterday at $5.17.
According to TipRanks, Miehm is an analyst with an average return of -2.1% and a 38.64% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Bausch + Lomb Corporation, and Aurinia Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $10.00 average price target, which is a 93.42% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.
The company has a one-year high of $12.43 and a one-year low of $4.71. Currently, Aurinia Pharmaceuticals has an average volume of 2.1M.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AUPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals (AUPH) Company Description:
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Read More on AUPH:
